ライフサイエンスコーパス: anticardiolipin antibody

1 ding; and those who had detectable levels of anticardiolipin antibodies.

2 Recently, anticardiolipin antibodies (ACA) have been linked with c

3 e (APAS) is characterized by the presence of anticardiolipin antibodies (ACA) in association with thr

4 Antiphospholipid antibodies, including anticardiolipin antibodies (ACA), are strongly associate

5 trongly that lupus anticoagulants (LACs) and anticardiolipin antibodies (ACAs) are antibodies to prot

6 lls treated with a range of human monoclonal anticardiolipin antibodies (aCL) (as anti-beta2-glycopro

7 Yet, standard anticardiolipin antibodies (aCL) immunoassays routinely

8 anti-beta2-glycoprotein I (anti-beta2GPI) or anticardiolipin antibodies (aCL) may be implicated in th

9 Mice infused with IgG containing human anticardiolipin antibodies (aCL) were treated with IVIG

10 Anti-MDA-LDL, anticardiolipin antibodies (aCL), and anti-beta2-glycopr

11 A, C, B/B', and D, for anti-U1 RNA, and for anticardiolipin antibodies (aCL).

12 had lupus anticoagulant and/or high titer of anticardiolipin antibodies (aCL).

13 , thrombin, APC, and plasmin, as well as for anticardiolipin antibody (aCL) activity.

14 rotein AI to OxCL-coated wells increased the anticardiolipin antibody (aCL) binding from APS sera tha

15 uble-stranded DNA (anti-dsDNA) antibody, and anticardiolipin antibody (aCL), as well as proteinuria a

16 La, anti-RNP, lupus anticoagulant (LAC), and anticardiolipin antibody [aCL]) were selected for cluste

17 d lupus anticoagulant (LA) or high titers of anticardiolipin antibodies (ACLAs), either immunoglobuli

18 Anticardiolipin antibodies and anti-beta2GPI were presen

19 otein(a), homocysteine, lupus anticoagulant, anticardiolipin antibodies and genotyping of factor V Le

20 f CL is needed to generate epitopes for many anticardiolipin antibodies and that some of these epitop

21 atients with stroke associated with elevated anticardiolipin antibodies, and we discuss their managem

22 ter IgG or IgM anticardiolipin antibody, IgA anticardiolipin antibody, and anti-beta2-glycoprotein I

23 Anticardiolipin antibodies (antiCl), present in some pat

24 Anticardiolipin antibodies appeared from 7.6 years prior

25 Our findings indicate that anticardiolipin antibodies are frequently elevated in pa

26 iciency, activated protein C resistance, and anticardiolipin antibodies) at predictably greater risk

27 Ls were measured longitudinally: 3 in serum (anticardiolipin antibodies, beta2-glycoprotein I, and an

28 We recently suggested that many anticardiolipin antibodies bind only to oxidized cardiol

29 nd 1 patient each with protein C deficiency, anticardiolipin antibodies, factor VII mutation, factor

30 relationship between dyslipoproteinemia and anticardiolipin antibodies has been demonstrated.

31 and technical complications, but the role of anticardiolipin antibodies has not been evaluated.

32 Lupus anticoagulants and anticardiolipin antibodies have been strongly associated

33 strated that human monoclonal and polyclonal anticardiolipin antibodies have thrombogenic properties

34 aris, thrombocytopenia, low-titer IgG or IgM anticardiolipin antibody, IgA anticardiolipin antibody,

35 nt with acute Q fever and high levels of IgG anticardiolipin antibodies (IgG aCL).

36 ted the possible association between HAT and anticardiolipin antibodies in adult patients who underwe

37 Other potential consequences of anticardiolipin antibodies in end-stage liver disease re

38 Anticardiolipin antibodies in SLE patients tend to prece

39 luded if they had moderate or high levels of anticardiolipin antibodies, lupus anticoagulant, or a hi

40 of Raynaud's phenomenon, as well as elevated anticardiolipin antibodies, lupus anticoagulant, or a hi

41 e not generalizable to women with high-titer anticardiolipin antibodies, lupus anticoagulant, or prev

42 Antiphospholipid antibodies including anticardiolipin antibodies, lupus anticoagulants, and an

43 ity for lupus anticoagulant (P < 0.0001) and anticardiolipin antibodies of the IgG (P = 0.035) or the

44 and the presence of the lupus anticoagulant, anticardiolipin antibodies, or anti-beta(2)-glycoprotein

45 in lymphocyte count or serum immunoglobulin, anticardiolipin antibody, or rubella IgG antibody concen

46 of 35 (63%) liver recipients had a positive anticardiolipin antibody test (either IgG or IgM titer >

47 either the lupus anticoagulant titer or the anticardiolipin antibody titer on two occasions, separat

48 Determination of IgM and IgG anticardiolipin antibodies was performed by enzyme-linke

49 ng anticoagulant therapy in patients with an anticardiolipin antibody was 1.53 (95% CI, 0.76-3.11), a

50 coagulable state associated with circulating anticardiolipin antibodies, which prompted discontinuati